Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69 Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan.
Digestive Disease Centre, Showa University, Koto-Toyosu Hospital, Tokyo, Japan.
J Gastroenterol. 2019 Jan;54(1):1-9. doi: 10.1007/s00535-018-1491-x. Epub 2018 Jun 30.
Endoscopic surveillance of Barrett's esophagus has become a foundation of the management of esophageal adenocarcinoma (EAC). Surveillance for Barrett's esophagus commonly involves periodic upper endoscopy with biopsies of suspicious areas and random four-quadrant biopsies. However, targeted biopsies using narrow-band imaging can detect more dysplastic areas and thus reduce the number of biopsies required. Several specific mucosal and vascular patterns characteristic of Barrett's esophagus have been described, but the proposed criteria are complex and diverse. Simpler classifications have recently been developed focusing on the differentiation between dysplasia and non-dysplasia. These include the Japan Esophageal Society classification, which defines regular and irregular patterns in terms of mucosal and vascular shapes. Cancer invasion depth is diagnosed by endoscopic ultrasonography (EUS); however, a meta-analysis of EUS staging of superficial EAC showed favorable pooled values for mucosal cancer staging, but unsatisfactory diagnostic results for EAC at the esophagogastric junction. Endoscopic resection has recently been suggested as a more accurate staging modality for superficial gastrointestinal cancers than EUS. Following endoscopic resection for gastrointestinal cancers, the risk of metastasis can be evaluated based on the histology of the resected specimen. European guidelines describe endoscopic resection as curative for well- or moderately differentiated mucosal cancers without lymphovascular invasion, and these criteria might be extended to lesions invading the submucosa (≤ 500 μm), i.e., to low-risk, well- or moderately differentiated tumors without lymphovascular involvement, and < 3 cm. These criteria were confirmed by a recent study in Japan.
内镜监测 Barrett 食管已成为食管腺癌(EAC)管理的基础。Barrett 食管的监测通常包括定期进行上消化道内镜检查,对可疑区域进行活检和随机进行四个象限的活检。然而,使用窄带成像的靶向活检可以检测到更多的异型增生区域,从而减少所需的活检数量。已经描述了几种 Barrett 食管特有的黏膜和血管模式,但提出的标准复杂且多样。最近开发了更简单的分类方法,重点关注异型增生和非异型增生的区分。其中包括日本食管学会分类,它根据黏膜和血管形状定义了规则和不规则模式。癌症浸润深度通过内镜超声(EUS)诊断;然而,EUS 对浅表 EAC 的分期的荟萃分析显示,黏膜癌分期的汇总值有利,但食管胃交界处 EAC 的诊断结果并不令人满意。最近有人建议内镜切除作为比 EUS 更准确的浅表胃肠道癌症分期方法。在胃肠道癌症的内镜切除后,可以根据切除标本的组织学来评估转移的风险。欧洲指南将无淋巴管血管侵犯的分化良好或中度分化的黏膜癌的内镜切除定义为治愈性的,这些标准可能会扩展到侵犯黏膜下层(≤500μm)的病变,即低风险、分化良好或中度分化、无淋巴管血管侵犯、且<3cm 的肿瘤。这些标准最近在日本的一项研究中得到了证实。
Gastrointest Endosc. 2005-7
World J Gastroenterol. 2023-12-28
Case Rep Oncol. 2023-10-31
Cancers (Basel). 2023-1-26
Diagnostics (Basel). 2023-1-16
Endosc Int Open. 2022-8-15
Br J Cancer. 2022-3
J Gastrointest Surg. 2016-4